17
Participants
Start Date
August 31, 2010
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Biostate
"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
Study site, Bremen
Study site, Minsk
Study site, Homyel
Study site, Tbilisi
Study site, Guatemala City
Study site, Beirut
Study Site, Lviv
Lead Sponsor
Collaborators (1)
Parexel
INDUSTRY
CSL Behring
INDUSTRY